A randomized, open-label, multiple-dose, crossover phase I study to compare the pharmacokinetic characteristics and safety of Dilatrend SR capsule 32 mg and Dilatrend tablet 25 mg

Trial Profile

A randomized, open-label, multiple-dose, crossover phase I study to compare the pharmacokinetic characteristics and safety of Dilatrend SR capsule 32 mg and Dilatrend tablet 25 mg

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Carvedilol (Primary)
  • Indications Angina pectoris; Essential hypertension; Heart failure
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Jul 2013 New source identified and integrated (Korean Clinical Trials Register: KCT0000787).
    • 31 Jul 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by Korean Clinical Trials Register record.
    • 05 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top